Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available
Matthias Samwald(Konrad Lorenz Institute for Evolution and Cognition Research), Richard D. Boyce(University of Pittsburgh), Patrick Ryan(Johnson & Johnson (United States)), Daniel C. Malone(University of Arizona), Sebastian J. Hofer(Max Delbrück Center), Seid Mussa Ahmed(Jimma University), Hong Xu(Kidney Associates), Philip E. Empey(University of Pittsburgh), Kathrin Blagec(Austrian Research Institute for Artificial Intelligence)
Cited by 81
Related Papers
The BioPAX community standard for pathway data sharing
|Nature Biotechnology|2010|756
Caloric Restriction Mimetics against Age-Associated Disease: Targets, Mechanisms, and Therapeutic Potential
|Cell Metabolism|2019|604
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study
|The Lancet|2023|508